2016 Press Releases

Home»2016 Press Releases
12 12, 2016

Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH)

2017-02-07T16:45:01+00:00

Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH) - Positive Interim Data from Phase 2 Multiple-Ascending Dose Study - Novel Liquid Formulation of Exendin 9-39 - US Orphan Designation for Hyperinsulinemic Hypoglycemia PALO ALTO, Calif., December 12, 2016 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development [...]

Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH)2017-02-07T16:45:01+00:00
29 11, 2016

Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH)

2017-02-07T16:46:23+00:00

Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH) - Exendin 9-39 investigational new drug (IND) application filed - PBH Analyst / Key Opinion Leader Event planned December 9th - Multiple-ascending dose (MAD) study interim data to be presented PALO ALTO, Calif., November 29, 2016 — Eiger BioPharmaceuticals, [...]

Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH)2017-02-07T16:46:23+00:00
17 11, 2016

Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting

2017-02-07T17:05:50+00:00

Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting - Update on Data Presented and Analyst Meeting through Monday Evening PALO ALTO, Calif., November 14, 2016 -- Eiger BioPharmaceuticals, Inc, (NASDAQ: EIGR) today announced presentation of additional data from the LOWR HDV [...]

Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting2017-02-07T17:05:50+00:00
14 11, 2016

Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program

2017-02-07T17:07:41+00:00

Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program - Data Presented through Monday Morning PALO ALTO, Calif., November 14, 2016 -- Eiger BioPharmaceuticals, Inc, (NASDAQ: EIGR) today announced an update on presentations of [...]

Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program2017-02-07T17:07:41+00:00
8 11, 2016

Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results

2017-02-07T17:10:04+00:00

Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results Data from Multi-center, International LOWR HDV (LOnafarnib With Ritonavir in HDV) Phase 2 Program to be Presented at AASLD 2016  Eiger Hosted LOWR HDV Program Key Opinion Leader Review at AASLD 2016  Four Product Candidates in Four Orphan Indications Continuing to Advance PALO ALTO, Calif., November [...]

Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results2017-02-07T17:10:04+00:00
24 10, 2016

Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection

2017-02-07T17:11:55+00:00

Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection - Collaboration with ARUP Laboratories and Hepatitis B Foundation - HDV viral load assay now available in U.S. PALO ALTO, Calif., October 24, 2016, Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a clinical-stage biopharmaceutical company focused on the development and [...]

Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection2017-02-07T17:11:55+00:00
19 10, 2016

Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection

2017-02-07T17:17:55+00:00

Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection - LIMT HDV: Lambda Interferon MonoTherapy in HDV Study PALO ALTO, Calif., October 19, 2016 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first [...]

Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection2017-02-07T17:17:55+00:00
17 10, 2016

Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)

2017-02-07T17:19:37+00:00

Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA) PALO ALTO, Calif., October 17, 2016 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today that the European Medicines Agency (EMA) has granted orphan designation to [...]

Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)2017-02-07T17:19:37+00:00
13 10, 2016

Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting

2017-02-07T17:21:24+00:00

Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting PALO ALTO, Calif., October 13, 2016 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program will be presented at the American Association [...]

Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting2017-02-07T17:21:24+00:00
7 09, 2016

Eiger Announces Completion of Dosing in Phase 2 LOWR HDV – 4 Study at Hannover Medical School

2017-02-07T17:23:07+00:00

Eiger Announces Completion of Dosing in Phase 2 LOWR HDV – 4 Study at Hannover Medical School PALO ALTO, Calif., September 7, 2016 /PR Newswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the completion of dosing of LOWR [...]

Eiger Announces Completion of Dosing in Phase 2 LOWR HDV – 4 Study at Hannover Medical School2017-02-07T17:23:07+00:00